Celltrion USA today announced that STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo), biosimilars referencing PROLIA® ...

New criteria make high-risk smoldering multiple myeloma treatable, opening door to future 'chronic' disease status ...

Fresenius Kabi’s fifth and sixth biosimilars Conexxence (denosumab-bnht) and Bomyntra (denosumab-bnht) have launched in the ...

Fatigue, bone pain, and frequent infections can all be signs of the blood cancer multiple myeloma, which often has no early distinctive symptoms.

Kyphoplasty is being used to treat painful osteolytic or fractured vertebrae, but will it become a key treatment option for patients with vertebral osteolyses from multiple myeloma?

The clinical presentation of multiple myeloma varies widely. Some patients are asymptomatic, with the disease discovered through routine blood tests, while others present with severe symptoms such as ...

In spite of recent advances in the management of multiple myeloma, cure has been elusive, with efforts to improve long-term outcomes thwarted by repeated cycles of relapse and remission.

NICE leads the way in approving breakthrough treatment for multiple myeloma People in England will become the first in the world to receive belantamab mafodotin for this indication following our ...

International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma The following represents disclosure information provided by ...

Sundar Jagannath, MBBS, highlights long-term follow-up data from the phase 1b/2 CARTITUDE-1 trial, showing durable responses and potential cures with ciltacabtagene autoleucel in patients with ...

Celltrion USA announced that Stoboclo (denosumab-bmwo) and Osenvelt (denosumab-bmwo), biosimilars referencing Prolia ...